TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36675280

Group type: EXPERIMENTAL
Intervention: High total polyunsaturated fatty acid (PUFA) content in abdominal adipose tissue
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low total polyunsaturated fatty acid (PUFA) content in abdominal adipose tissue
Number of subjects: 52
Study: 36675633

Group type: EXPERIMENTAL
Intervention: Patients with heart disease
Number of subjects: 7014

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Number of subjects: 7014

Group type: COMPARATOR
Intervention: Patients without cardiovascular disease
Number of subjects: 7014
Study: 36678170

Group type: EXPERIMENTAL
Intervention: 100 mg/day ISF Supplement
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 50 mg/day ISF Diet
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: ISF Supplement among women enrolled within 5 years of menopause
Number of subjects: 118
Study: 36678191

Group type: EXPERIMENTAL
Intervention: 800 mg of EGCG daily alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 800 mg of EGCG daily with clomiphene citrate 100 mg for 5 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 800 mg of EGCG daily with Letrozole 5 mg for 5 days
Number of subjects: 39
Study: 36678312

Group type: EXPERIMENTAL
Intervention: Dexamethasone exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin A status
Number of subjects: 0
Study: 36678638

Group type: EXPERIMENTAL
Intervention: Rifampicin at 35 mg/kg (HR35ZE group)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Rifampicin at 10 mg/kg (historical HR10ZE group)
Number of subjects: 134
Study: 36678659

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy applied once a week for four sessions with orabase cream
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-power laser application with orabase cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inactive laser with triamcinolone acetonide 0.1%
Number of subjects: 60
Study: 36679862

Group type: EXPERIMENTAL
Intervention: MVC-COV1901 vaccine (two doses, 28 days apart)
Number of subjects: 57
Study: 36680319

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36680419

Group type: EXPERIMENTAL
Intervention: Nalbuphine extended release (ER) 108 mg BID
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Nalbuphine extended release (ER) 162 mg BID
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 36680576

Group type: EXPERIMENTAL
Intervention: SWL with Virtual Reality (VR)
Number of subjects: 166

Group type: COMPARATOR
Intervention: SWL without Virtual Reality (VR)
Number of subjects: 166
Study: 36680581

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg + Palbociclib
Number of subjects: 354

Group type: COMPARATOR
Intervention: Fulvestrant 500 mg + Placebo
Number of subjects: 354
Study: 36680617

Group type: EXPERIMENTAL
Intervention: Self-expanding valve (n=103)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Balloon-expanding valve (n=100)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Electrophysiologic study (EPS) of atrioventricular conduction
Number of subjects: 203
Study: 36680620

Group type: EXPERIMENTAL
Intervention: Ciprofol-0.3 mg/kg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Ciprofol-0.4 mg/kg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Ciprofol-0.5 mg/kg
Number of subjects: 109

Group type: COMPARATOR
Intervention: Propofol-2.0 mg/kg
Number of subjects: 109

Group type: COMPARATOR
Intervention: Propofol-2.5 mg/kg
Number of subjects: 109
Study: 36680884

Group type: EXPERIMENTAL
Intervention: NAVA-NIV
Number of subjects: 76

Group type: COMPARATOR
Intervention: ASV-NIV
Number of subjects: 76
Study: 36680919

Group type: EXPERIMENTAL
Intervention: 800 mg DHA
Number of subjects: 1100

Group type: COMPARATOR
Intervention: 200 mg DHA
Number of subjects: 1100
Study: 36681013

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus Trastuzumab (P + T)
Number of subjects: 4769

Group type: COMPARATOR
Intervention: Trastuzumab (T)
Number of subjects: 4769
Study: 36681089

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 36681093

Group type: EXPERIMENTAL
Intervention: ABNCoV2 vaccine (6 μg, 12 μg, 25 μg, 50 μg, or 70 μg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ABNCoV2 vaccine (25-70 μg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ABNCoV2 vaccine
Number of subjects: 45
Study: 36681160

Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated perfusion (HOPE) for 1-2 hours before implantation
Number of subjects: 170

Group type: COMPARATOR
Intervention: Conventional cold storage (control group)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated perfusion (HOPE)
Number of subjects: 170
Study: 36681173

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) only
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy with ASA and ticagrelor
Number of subjects: 2200
Study: 36681238

Group type: EXPERIMENTAL
Intervention: Link for Equity program (trauma-informed care and cultural humility)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: One-on-one support from trained school staff
Number of subjects: 188

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 188
Study: 36681255

Group type: EXPERIMENTAL
Intervention: Revefenacin 175 μg
Number of subjects: 812

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 812
Study: 36681446

Group type: EXPERIMENTAL
Intervention: Low-dose BMMNC
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High-dose BMMNC
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Pooled BMMNC
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 77
Study: 36681445

Group type: EXPERIMENTAL
Intervention: leriglitazone (150 mg starting dose, adjusted to achieve plasma concentrations of 200 μg·h/mL)
Number of subjects: 116

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: leriglitazone
Number of subjects: 116
Study: 36681529

Group type: EXPERIMENTAL
Intervention: TAK-003 and HAV vaccine on Day 1, TAK-003 on Day 90 (Group 3)
Number of subjects: 900

Group type: COMPARATOR
Intervention: HAV vaccine and placebo on Day 1, placebo on Day 90 (Group 1)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: TAK-003 and placebo on Day 1, TAK-003 on Day 90 (Group 2)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Group 1 (HAV vaccine)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Group 3 (TAK-003 and HAV vaccine)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: TAK-003 recipients
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Coadministration of HAV vaccine and TAK-003
Number of subjects: 900
Study: 36681798

Group type: EXPERIMENTAL
Intervention: Metformin extended release (1000 mg/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 36681813

Group type: EXPERIMENTAL
Intervention: CyPath Lung test using automated flow cytometry and machine learning
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CyPath Lung test for nodules < 20 mm
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CyPath Lung test on independent second set of samples
Number of subjects: 150
Study: 36681817

Group type: EXPERIMENTAL
Intervention: ET019003 cells
Number of subjects: 8
Study: 36682012

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination during pregnancy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Unvaccinated during pregnancy
Number of subjects: 500
Study: 36682096

Group type: EXPERIMENTAL
Intervention: ODX 3 mg/kg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ODX 6 mg/kg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ODX 9 mg/kg
Number of subjects: 55
Study: 36682144

Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watchful waiting with supportive care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 36682262

Group type: EXPERIMENTAL
Intervention: Azithromycin (once-weekly oral, weight-based dosing for 48 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36682343

Group type: EXPERIMENTAL
Intervention: Preoperative Mobile Gamma Camera (MGC) imaging
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intraoperative Mobile Gamma Camera (MGC) imaging
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Preoperative MGC imaging compared to FGC images
Number of subjects: 20
Study: 36682364

Group type: EXPERIMENTAL
Intervention: mRNA-1325 10 μg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: mRNA-1893 100 μg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: mRNA-1893 10 μg and 100 μg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: mRNA-1893 (all dose levels)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 36682492

Group type: EXPERIMENTAL
Intervention: Digital storytelling intervention (12-min video and five monthly text messages)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Usual diabetes care
Number of subjects: 451
Study: 36682596

Group type: EXPERIMENTAL
Intervention: Interruption of β-blocker therapy
Number of subjects: 3700

Group type: COMPARATOR
Intervention: Continuation of β-blocker therapy
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Evaluation of quality of life using EQ5D-5L questionnaire
Number of subjects: 3700
Study: 36682595

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 48

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 48
Study: 36682675

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) intervention, single session for 20-45 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post-MT satisfaction survey (n=14)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post-MT effectiveness measures (n=14)
Number of subjects: 20
Study: 36682681

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 600 mg twice on day 1, followed by 400 mg daily for 29 days.
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Placebo (matched to HCQ).
Number of subjects: 1360
Study: 36682889

Group type: EXPERIMENTAL
Intervention: Niacin treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy women
Number of subjects: 45
Study: 36682908

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF)
Number of subjects: 688

Group type: COMPARATOR
Intervention: 5% sodium fluoride varnish (FV)
Number of subjects: 688
Study: 36682909

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 2650

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2650
Study: 36683090

Group type: EXPERIMENTAL
Intervention: 20 mg of escitalopram (n=32)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (n=34)
Number of subjects: 66
Study: 36683132

Group type: EXPERIMENTAL
Intervention: Point-of-care HCV RNA testing
Number of subjects: 24
Study: 36683179

Group type: EXPERIMENTAL
Intervention: PA Plus RTR (12-week PA telephone counseling delivered by RTR volunteers)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 36683291

Group type: EXPERIMENTAL
Intervention: KW-6356 (specific dosage and duration not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific details not available)
Number of subjects: 0
Study: 36683376

Group type: EXPERIMENTAL
Intervention: Distance caregiving
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effective communication between hospice teams and family caregivers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregiver proximity
Number of subjects: 0
Study: 36683419

Group type: EXPERIMENTAL
Intervention: AZD7442 (300 mg intramuscularly)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (salt solution)
Number of subjects: 60
Study: 36683588

Group type: EXPERIMENTAL
Intervention: Acculturation (Spanish language preference)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Dietary quality (USDA Healthy Eating Index)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Fat avoidance (Fat Avoidance Scale, Spanish version)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Macronutrient intake
Number of subjects: 300
Study: 36683707

Group type: EXPERIMENTAL
Intervention: Capsulized fecal microbiota transplantation (FMT) three times a week
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Capsulized fecal microbiota transplantation (FMT)
Number of subjects: 22
Study: 36683766

Group type: EXPERIMENTAL
Intervention: IAP0971
Number of subjects: 0
Study: 36684605

Group type: EXPERIMENTAL
Intervention: Triglyceride-rich LDL (LDL-TG)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Genetic variants in the genomic region encoding hepatic lipase (LIPC)
Number of subjects: 665
Study: 36684710

Group type: EXPERIMENTAL
Intervention: Strength-based rehabilitation programme
Number of subjects: 88

Group type: COMPARATOR
Intervention: Combination of power and strength-based exercises
Number of subjects: 88
Study: 36684876

Group type: EXPERIMENTAL
Intervention: Getting To Outcomes (GTO) adapted to Getting To Implementation (GTI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GTI
Number of subjects: 0
Study: 36685065

Group type: EXPERIMENTAL
Intervention: High intensity exercise for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36685528

Group type: EXPERIMENTAL
Intervention: Targeted-release formulation (TRF) of budesonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic corticosteroid treatment
Number of subjects: 0
Study: 36685541

Group type: EXPERIMENTAL
Intervention: Serplulimab plus chemotherapy (etoposide and carboplatin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 0
Study: 36686334

Group type: EXPERIMENTAL
Intervention: My EMI, Emotional Well-being app
Number of subjects: 30
Study: 36686592

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin (HCV genotype 2, n = 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ledipasvir (HCV genotypes 1 and 4, n = 80)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-based DAA therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study: 36686613

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (IVR) for ULMI home rehabilitation
Number of subjects: 0
Study: 36686711

Group type: EXPERIMENTAL
Intervention: Evolocumab, dosage and duration not available
Number of subjects: 0
Study: 36686792

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticle suspension injection (CNSI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Indocyanine green (ICG)
Number of subjects: 96
Study: 36687215

Group type: EXPERIMENTAL
Intervention: E-learning intervention consisting of three modules administered at baseline, 6 and 12 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 36687394

Group type: EXPERIMENTAL
Intervention: Multicomponent singing intervention
Number of subjects: 54
Study: 36687403

Group type: EXPERIMENTAL
Intervention: COVID-19 Rehab Formula (CRF) along with certain pre-defined Chinese medicine for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 0
Study: 36687442

Group type: EXPERIMENTAL
Intervention: Modified tarsorrhaphy (MT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Gold weight implant (GWI)
Number of subjects: 23
Study: 36687447

Group type: EXPERIMENTAL
Intervention: Lung clearance index by multiple breath washout
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semi-quantitative magnetic resonance imaging scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequency of pulmonary exacerbations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infection with pro-inflammatory pathogens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthropometric data
Number of subjects: 0
Study: 36687454

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme supplements (PES) - pancrelipase co-administered with omeprazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo - omeprazole only
Number of subjects: 12
Study: 36687671

Group type: EXPERIMENTAL
Intervention: Akovita SCT (butyrate and hexanoate esterified with long chain fatty acids)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tributyrin/caproin (solely butyrate and hexanoate)
Number of subjects: 0
Study: 36687807

Group type: EXPERIMENTAL
Intervention: Individual video-based case conceptualization with a web-based program based on Acceptance and Commitment Therapy (ACT), combined with treatment as usual.
Number of subjects: 124

Group type: COMPARATOR
Intervention: Treatment as usual only.
Number of subjects: 124
Study: 36687887

Group type: EXPERIMENTAL
Intervention: MCRR therapy for 20 minutes and pelvic floor exercises for 20 minutes, three times a week for 4 weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment (same application as in Group A without emitting any waves) for 20 minutes, three times a week for 4 weeks.
Number of subjects: 40
Study: 36688305

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure control (<120 mm Hg)
Number of subjects: 8663

Group type: COMPARATOR
Intervention: Standard systolic blood pressure control (<140 mm Hg)
Number of subjects: 8663
Study: 36688367

Group type: EXPERIMENTAL
Intervention: Ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 0
Study: 36688371

Group type: EXPERIMENTAL
Intervention: MEDI6570 (10, 30, 90, 250, or 500 mg single ascending doses; 90, 150, or 250 mg multiple ascending doses once monthly for 3 months)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: MEDI6570 (after 3 doses)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 36688507

Group type: EXPERIMENTAL
Intervention: Restrictive fluid strategy
Number of subjects: 1563

Group type: COMPARATOR
Intervention: Liberal fluid strategy
Number of subjects: 1563
Study: 36688692

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 36688719

Group type: EXPERIMENTAL
Intervention: Intervention details not available
Number of subjects: 0
Study: 36689092

Group type: EXPERIMENTAL
Intervention: DTC-positive patients
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Pathologic complete response (pCR)
Number of subjects: 73
Study: 36689215

Group type: EXPERIMENTAL
Intervention: Disposable elevator cap duodenoscopes
Number of subjects: 518

Group type: COMPARATOR
Intervention: Standard duodenoscopes
Number of subjects: 518
Study: 36689214

Group type: EXPERIMENTAL
Intervention: Biosimilar natalizumab (biosim-NTZ), 300 mg, intravenous infusion every 4 weeks from week 0 to week 44.
Number of subjects: 264

Group type: COMPARATOR
Intervention: Reference natalizumab (ref-NTZ), 300 mg, intravenous infusion every 4 weeks from week 0 to week 44.
Number of subjects: 264
Study: 36689272

Group type: EXPERIMENTAL
Intervention: Multiplayer game-based intervention
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control condition (time and attention control game)
Number of subjects: 79
Study: 36689306

Group type: EXPERIMENTAL
Intervention: Weight loss smartphone apps
Number of subjects: 22
Study: 36689305

Group type: EXPERIMENTAL
Intervention: Virtual synchronous and virtual asynchronous intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 60
Study: 36689336

Group type: EXPERIMENTAL
Intervention: Digital communication technology intervention (including computerized phone calls, texts, and email)
Number of subjects: 0
Study: 36689337

Group type: EXPERIMENTAL
Intervention: Alopecia areata (AA) group
Number of subjects: 8051
Study: 36689557

Group type: EXPERIMENTAL
Intervention: Tough Talks for COVID-19 digital health intervention
Number of subjects: 360

Group type: COMPARATOR
Intervention: Standard-of-care control condition
Number of subjects: 360
Study: 36689588

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 1321
Study: 36689671

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Number of subjects: 95

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 95
Study: 36689692

Group type: EXPERIMENTAL
Intervention: Tarlatamab (AMG 757), administered in dose exploration (0.003 to 100 mg; n = 73) and expansion (100 mg; n = 34) cohorts
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Tarlatamab (AMG 757)
Number of subjects: 107
Study: 36689698

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 113

Group type: COMPARATOR
Intervention: Non-TRK-inhibitor SoC
Number of subjects: 113
Study: 36689726

Group type: EXPERIMENTAL
Intervention: Acalabrutinib and high-frequency low-dose (HFLD) subcutaneous rituximab 50 mg administered twice a week for 6 cycles of 28 days
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Acalabrutinib monotherapy
Number of subjects: 38
Study: 36689746

Group type: EXPERIMENTAL
Intervention: High-dose exercise therapy (patient-tailored exercise programs, 3 times a week for 12 weeks)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: High-dose exercise therapy
Number of subjects: 189

Group type: COMPARATOR
Intervention: Low-dose exercise therapy (patient-tailored exercise programs, 3 times a week for 12 weeks)
Number of subjects: 189
Study: 36689927

Group type: EXPERIMENTAL
Intervention: rPAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard T-piece
Number of subjects: 0
Study: 36690030

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 203

Group type: COMPARATOR
Intervention: White-light endoscopy (WLE)
Number of subjects: 203
Study: 36690072

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (Hb <10 g/dL to Hb ≥10 g/dL)
Number of subjects: 1520

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (Hb <7 g/dL to Hb ≥7 g/dL)
Number of subjects: 1520